Beyond Air (XAIR) Q4 FY26 earnings call

New CEO Robert Goodman's first call marks a deliberate narrowing of Beyond Air to the LungFit PH franchise: a restructured cost base and a sticky, high-renewal hospital installed base now serve as the platform for the Gen 2 system, whose transport-capable label — if FDA-approved — is the investment thesis, materially expanding the addressable market. Guidance debuts on a new calendar-year basis, with the real revenue inflection deferred to 2027 and explicitly contingent on approval.